Owners, management and financials
CVR: 44689790
DKK 22,056,673
Gross profit
Net result: DKK 2,096,582
Novo Holdings A/S (5-9,99%), Alveus Therapeutics Inc. (66,66-89,99%)
3 more
CVR · view owners
Rajkumar Kannan
CVR · view management
Active
Founded 5 March 2024
CVR · view overview
2 employees
Annual report 2025 · average
Owner registered: Novo Holdings A/S
CVR · 24/07/2026
View the full event history
Alveus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Rajkumar Kannan. The company's owners include Novo Holdings A/S, Alveus Therapeutics Inc. and FPCI BioDiscovery 7. According to the 2025 annual report, the company had an average of 2 employees. In 2025, the company reported a gross profit of DKK 22,056,673 and a net result of DKK 2,096,582 compared with DKK -5,608,478 the year before. Equity in the 2025 report amounted to DKK 59,681,194.
Source: annual report 2025, Danish Business Authority
The financial health of Alveus Therapeutics ApS shows a significant turnaround from 2024 to 2025. In 2025, the company reported a gross profit of 22,056,673 DKK and a profit of 2,096,582 DKK, indicating a positive trajectory after a challenging start with a gross loss of 968,913 DKK and a net loss of 5,608,478 DKK in 2024. Equity has improved substantially, reaching 59,681,194 DKK, suggesting a strong recovery and a solid foundation for future growth. However, the lack of disclosed revenue figures raises concerns about market position and operational scale within the research and experimental development sector.
AI-generated summary · Generated 13/08/2026
Selskabets formål er at drive virksomhed med forskning og eksperimentel udvikling indenfor bioteknologi.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 22.1 mio. | 2.1 mio. | 65.1 mio. | 59.7 mio. | 2 | |
| 202405/03/2024 – 31/12/2024 | -969 t. | -5.6 mio. | 480 t. | -5.6 mio. | 3 |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Alveus Therapeutics ApS is 44689790.
The owners of Alveus Therapeutics ApS include Novo Holdings A/S, Alveus Therapeutics Inc. and FPCI BioDiscovery 7.
The management of Alveus Therapeutics ApS consists of Rajkumar Kannan.
In 2025, Alveus Therapeutics ApS reported a gross profit of DKK 22,056,673.
Alveus Therapeutics ApS had an average of 2 employees in the 2025 financial year according to the annual report.
Alveus Therapeutics ApS was founded on 5 March 2024.
Claim this page to add your logo and social links. Free to get started.
As of July 24, 2026, Novo Holdings A/S is registered as an owner of Alveus Therapeutics ApS with an ownership share of 5%.
As of July 24, 2026, is registered as an owner of Alveus Therapeutics ApS with an ownership share of 5%.
Alveus Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK 22,056,673, and the net result was DKK 2,096,582.
As of February 23, 2026, is registered as an owner of Alveus Therapeutics ApS with an ownership share of 5%.
As of January 23, 2026, is registered as an owner of Alveus Therapeutics ApS with an ownership share of 66%.
As of December 22, 2025, is registered as an owner of Alveus Therapeutics ApS with an ownership share of 5%.
As of November 15, 2025, Erik Voorspoels has stepped down as director of Alveus Therapeutics ApS.
As of September 22, 2025, Erik Voorspoels is registered as director of Alveus Therapeutics ApS.
As of September 22, 2025, Marie Louise Lindegaard has stepped down as director of Alveus Therapeutics ApS.
Alveus Therapeutics ApS has published its interim report for the period March 5, 2024 – December 31, 2024.
As of April 30, 2025, Rajkumar Kannan is registered as adm. dir. of Alveus Therapeutics ApS.
As of April 30, 2025, Nayan Gregory Parekh has stepped down as adm. dir. of Alveus Therapeutics ApS.
As of December 11, 2024, Marie Louise Lindegaard is registered as director of Alveus Therapeutics ApS.
As of December 11, 2024, Lars Peter Brunse has stepped down as director of Alveus Therapeutics ApS.
As of March 5, 2024, Lars Peter Brunse is registered as director of Alveus Therapeutics ApS.
As of March 5, 2024, Nayan Gregory Parekh is registered as adm. dir. of Alveus Therapeutics ApS.
Alveus Therapeutics ApS was founded on March 5, 2024.
Companies in the same industry and area
CVR 44695065
CVR 29418888
CVR 29769796
CVR 34688605
CVR 34892970
